After the outbreak of the Korean war, the Kingdom of Sweden, a permanent neutral nation, dispatched the Swedish Red Cross Field Hospital(SRCFH) instead of armed forces for humanitarian support to the allied forces in South Korea. The Hospital consisted of about 170 Swedes, all volunteers. From the early part of the Korean War, SRCFH took part in the medical assistance in Busan. When the frontline advanced to northern Korea, the number of inflowing casualties to this field hospital decreased. At that time, earnest medical aid for civilians commenced, and many Koreans were treated in available beds in SRCFH. After the armistice in July 1953, SRCFH became the Swedish Hospital in Busan, serving not only the military but also civilians, and continued its humanitarian mission until April 1957 for the Korean who were suffering from a collapsed medical system inthe midst of war. When the Hospital returned to Sweden, it had treated over two million patients from twenty countries, including wounded UN allied force, Korean (south and north), Chinese prisoner of war and Korean civilian. Moreover, it left a transformative legacy, the National Medical Center in Seoul which was established in collaboration with other Scandinavian countries who dispatched medical assistance during the Korean War.
Altruism ; History, 20th Century ; Hospitals/history ; Humans ; Korea ; *Red Cross ; Sweden ; War

Objective: : Trigeminal neuralgia (TN) is a severe neuropathic condition that affects several elderly patients. It is characterized by uncontrolled pain that significantly impacts the quality of life of patients. Therefore, the condition should be treated as an emergency. In the majority of patients, pain can be controlled with medication; however, other treatment modalities are being explored in those who become refractory to drug treatment. The use of the trigeminal nerve block with a local anesthetic serves as an excellent adjunct to drug treatment. This technique rapidly relieves the patient of pain while medications are being titrated to effective levels. We report the efficacy and safety of percutaneous trigeminal nerve block in elderly patients with TN at our outpatient clinic. Methods: : Twenty-one patients older than 65 years with TN received percutaneous nerve block at our outpatient clinic. We used bupivacaine (1 mL/injection site) to block the supraorbital, infraorbital, superior alveolar, mental, and inferior alveolar nerves according to pain sites of patients. Results: : All patients reported relief from pain, which decreased by approximately 78% after 2 weeks of nerve block. The effect lasted for more than 4 weeks in 12 patients and for 6 weeks in two patients. There were no complications. Conclusion : Percutaneous nerve block procedure performed at our outpatient clinic provided immediate relief from pain to elderly patients with TN. The procedure is simple, has no serious side effects, and is easy to apply.

BACKGROUND: The aims of this study were to investigate the role of the Neurological Assessment of Neuro-Oncology (NANO) scale in predicting the prognosis of patients with glioblastoma, and compare these results to predicted data of the Karnofsky Performance Scale (KPS), and Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status. Additionally, we examined other prognostic factors in glioblastoma patients. METHODS: The medical records of 76 patients with a new diagnosis of histologically ascertained glioblastoma in the period from January 2002 to December 2015 at the authors' institution were retrospectively reviewed. Clinical factors, including epidemiologic, radiologic, and therapeutic values were reviewed as well as the performance status assessed by the KPS, ECOG/WHO performance status, and NANO scale. RESULTS: The mean overall survival was 19.8 months (95% confidence interval 15.2–25.4 months). At initial diagnosis, the mean value [±standard deviation (SD)] of KPS score, ECOG/WHO performance status, and NANO scale were 81 (±7.4), 1.3 (±0.6), and 7.3 (±3.8), respectively. Multivariate analysis for predicting survival showed odds ratios of KPS score, ECOG/WHO performance status, and NANO scale were 2.502 (≥80 vs. < 80; p=0.024), 1.691 (0–1 vs. 2–5; p=0.047), and 2.763 (0–7 vs. 8–23; p=0.020), respectively. At the time of progression, the mean value (±SD) of KPS score, ECOG/WHO performance status, and NANO scale were 69 (±8.2), 1.6 (±0.7), and 11.4 (±4.2), respectively; multivariate analysis for predicting survival showed that the odd ratios for KPS score, ECOG/WHO performance status, and NANO scale were 2.007 (≥80 vs. < 80; p=0.035), 1.321 (0–1 vs. 2–5; p=0.143), and 3.182 (0–7 vs. 8–23; p=0.002), respectively. CONCLUSION: The NANO scale provided a more detailed and objective measure of neurologic function than that currently used for predicting the prognosis of glioblastoma patients, especially at the time of progression.
Diagnosis ; Glioblastoma* ; Humans ; Medical Records ; Multivariate Analysis ; Odds Ratio ; Prognosis ; Retrospective Studies